WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SF 4940

Summary of SF 4940 (Minnesota, 2025-2026)

Purpose

SF 4940 requires coverage of medical services and prescription medications for the treatment of dementia. The bill aims to ensure that individuals with dementia have access to necessary medical treatments and prescribed drugs as part of their formal care plan, improving continuity of care and reducing barriers to treatment access.

Key Provisions and Changes

  • Coverage mandate for medical services: The bill obligates health plans to cover certain medical services used in the treatment and management of dementia. While the specific services covered are not listed in the available summary, typical provisions in similar bills include visits to healthcare professionals (e.g., physicians, neurologists, geriatricians), diagnostic testing, and non-pharmacologic therapy as part of standard dementia care.

  • Coverage mandate for prescription medications: Insurers must cover prescribed medications used to treat dementia. This would likely include cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) and NMDA receptor antagonist (memantine) where appropriate, along with any other medications approved for dementia management. The exact formulary inclusions and any exceptions or step therapy requirements are not specified in the summary provided.

  • Treatment-focused scope: The emphasis is on treatment-related services and medications rather than general health coverage. This aligns benefits with ongoing dementia management, potentially including therapies, care coordination, and symptom management.

  • Regulatory alignment: The bill would require insurer compliance with the new coverage requirements, potentially affecting health plans offered by commercial carriers, and possibly including state-regulated plans or managed care organizations subject to Minnesota law.

Who Would Be Affected

  • Individuals diagnosed with dementia who rely on private health insurance or state-regulated plans that fall under the bill’s coverage mandate.
  • Healthcare providers treating dementia patients, who would be able to prescribe medications and order covered medical services with the expectation that those services and drugs will be covered by insurance plans.
  • Insurers and managed care entities operating in Minnesota, which would need to adjust benefit designs, formularies, and claim adjudication to comply with the coverage requirements.

Procedural and Timeline Aspects

  • Introduced and referred: The bill was introduced on April 7, 2026, and referred to the Commerce and Consumer Protection committee.
  • Author and sponsors: Primary author addition on April 9, 2026; co-sponsors include Liz Boldon and Ann Johnson Stewart.
  • Next steps: If advanced, the bill would proceed through committee hearings, potential amendments, and floor votes in the Minnesota Senate. The bill’s timeline would depend on committee actions, budget cycles, and legislative calendar. Specific effective dates (e.g., when coverage would commence) are not provided in the current summary.

Observations

  • The summary does not list exact services, medications, or exemptions, nor does it specify whether the coverage applies to all health plans in Minnesota or only certain categories. Details such as cost-sharing, timelines for implementation, and any transition provisions are not included in the available information.
  • As a “coverage” bill, it focuses on ensuring access to dementia-related treatment across insured populations, potentially reducing out-of-pocket costs for patients and improving adherence to treatment plans.

If you’d like, I can provide a version with assumed typical coverage language (e.g., enumerated services, formulary inclusions, and appeal rights) once you provide the bill text or official summaries detailing the specific provisions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.